RSV Immunogenicity Study in the Elderly (RISE)

Summary

Respiratory syncytial virus (RSV) is a common cause of respiratory tract infections leading to hospitalizations in infants and in elderly. Arexvy is an approved vaccine for the prevention of RSV infection, however, data on its efficacy in individuals aged 80 years and older remain limited. This study aims to evaluate potential differences in immune responses to Arexvy vaccination between adults aged ≥80 years and those aged 60-65 years.

Timeline

Start

2025-08-25

Primary completion

2027-05-31

Completion

2029-05-31

Drugs

Indications